+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 17 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatments for metastatic castration-resistant prostate cancer mCRPC. This study evaluates the medicine ifinatamab deruxtecan I-DXd or MK-2400 compared to chemotherapy to see if it helps people live longer overall and without cancer progression. The trial is sponsored by Merck Sharp & Dohme LLC and focuses on men with advanced prostate cancer who have tried other therapies. Participants are randomly assigned to one of two groups. One group receives I-DXd at 12 mg per kg every three weeks through intravenous infusion, along with premedication to prevent nausea and vomiting. The other group receives docetaxel chemotherapy at 75 mgm every three weeks plus daily oral prednisone. Treatments continue until the cancer worsens, side effects are unacceptable, or treatment stops for other reasons. During the study, participants will have regular assessments to monitor overall survival and how long they live without cancer progression, up to about 36 months. Researchers will also track additional outcomes like time to subsequent therapies, response rates, pain progression, and side effects. Safety and treatment tolerability will be closely monitored throughout the trial, which may last up to six years for some participants.

Age: 18Years +MALEPhase 3
303 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are studying the safety, tolerability, and how LY3962681 behaves in the body pharmacokineticspharmacodynamics in healthy volunteers and patients with Parkinsons disease. The trial has two parts a Single Ascending Dose SAD study with healthy volunteers and a Multiple Ascending Dose MAD study with Parkinsons patients. This study is a Phase 1, randomized, double-blind, placebo-controlled trial sponsored by Prevail Therapeutics. In the SAD part, healthy volunteers receive a single intrathecal into spinal fluid dose of LY3962681 or placebo artificial cerebrospinal fluid. In the MAD part, Parkinsons patients receive two intrathecal doses of LY3962681 or placebo spaced 12 to 24 weeks apart. The SAD treatment period lasts one day, while the MAD treatment includes two dosing days spaced several months apart. Participants will undergo safety and tolerability assessments over follow-up periods up to 52 weeks after dosing. Evaluations include monitoring for serious and treatment-emergent adverse events, measuring drug levels in the body, and assessing changes in cerebrospinal fluid biomarkers related to Parkinsons disease. The total study duration may extend for up to 76 weeks, including treatment and follow-up phases.

Age: 30Years - 80YearsAll GendersPhase 1
16 locations
E

Actively Recruiting

Researchers are evaluating whether donanemab, given as an intravenous infusion, can slow down the worsening of thinking, learning, memory, attention, and daily functioning in people with early cognitive decline and features of dementia with Lewy bodies. This phase 2 study focuses on participants aged 55 to 85 who show evidence of both amyloid and alpha-synuclein brain pathology. The trial is randomized and placebo-controlled to compare donanemab against a placebo. Participants will receive either donanemab or a placebo via IV infusion during the study. The treatment period lasts up to 52 weeks, during which various clinical and biomarker assessments will be conducted. The study includes monitoring for drug concentrations and immune responses. Both groups receive infusions under a quadruple-masked design to ensure unbiased results. Throughout the one and a half year participation, participants will be regularly evaluated using cognitive and functional tests like the Clinical Dementia Rating scale, Alzheimers Disease Rating Scales, and brain imaging to measure amyloid plaque levels. Safety assessments include monitoring for adverse effects and antibody development. Study partners familiar with the participants daily abilities provide additional information. The study aims to observe changes from baseline over the 52-week treatment period.

Age: 55Years - 85YearsAll GendersPhase 2
72 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the safety, tolerability, and behavior of LY4006896 when given intravenously to healthy adults and people with Parkinsons disease. This study compares LY4006896 with a placebo to understand how the drug interacts with the body and its effects over time. The study includes both healthy volunteers and participants diagnosed with Parkinsons disease, aiming to collect important safety and pharmacokinetic data. Participants with Parkinsons disease will undergo up to four doses of LY4006896 or placebo during a screening period lasting up to 120 days, followed by treatment and follow-up lasting up to 61 weeks. Healthy participants will receive a single escalating dose or placebo in a screening period lasting up to 35 days and be followed for up to 48 weeks. The study involves random assignment to receive either LY4006896 or placebo, with single blinding to ensure unbiased results. Throughout the study, participants will have regular assessments including monitoring for serious or treatment-emergent adverse events, blood sampling for drug concentration measurement, and evaluations of Parkinsons disease-related markers such as alpha-synuclein in skin and cerebrospinal fluid. Participants will be followed for up to 78 weeks Parkinsons group or 53 weeks healthy group to evaluate safety and drug effects. The trial includes detailed cognitive assessments and eligibility screening to ensure participant safety and data reliability.

Age: 30Years - 85YearsAll GendersPhase 1
14 locations
E

Actively Recruiting

Immunoglobulin A nephropathy IgAN is a kidney disease where immune system proteins build up in the kidneys causing inflammation. This inflammation may lead to kidney damage over time and reduce kidney function. The study is evaluating how well mezagitamab changes protein levels in the urine compared to a placebo in adults with primary IgAN. It also aims to assess the safety and tolerability of mezagitamab and how it maintains kidney function long term compared to placebo. Participants are randomly assigned to one of two groups in the main study two-thirds will receive mezagitamab injections and one-third will receive placebo injections, both given subcutaneously for about 22 weeks. Additionally, an open-label group includes participants with varying protein levels or kidney function who receive mezagitamab similarly. The entire study lasts about 2 years, with treatment for 22 weeks followed by approximately 1.5 years of observation. During the study, participants will have regular clinic visits, including monthly check-ups during the observation period. Assessments include measuring changes in urine protein levels and kidney function over time. Safety and tolerability of the study drug will also be monitored throughout the trial. Participants may continue in the study for up to 104 weeks, with ongoing evaluations to track kidney health and proteinuria.

Age: 18Years +All GendersPhase 3
186 locations
G

Actively Recruiting

This research aims to understand adult patients with transthyretin-mediated amyloidosis with cardiomyopathy ATTR-CM who are treated with vutrisiran in everyday medical care. The study describes patients clinical characteristics, treatment approaches, quality of life, and healthcare usage while comparing the long-term effects of vutrisiran with other approved treatments for ATTR-CM. Participants diagnosed with ATTR-CM and starting treatment with vutrisiran or other approved therapies will be observed. The study is observational and does not involve administering treatments but follows patients receiving routine care. Patients will be tracked for up to five years, including monitoring treatment patterns and patient experiences. During the study, participants will be regularly assessed for heart function using the New York Heart Association NYHA classification and other patient-reported measures such as quality of life questionnaires and treatment satisfaction surveys. Data will be collected from enrollment until five years or until withdrawal, loss to follow-up, or death, whichever occurs first. This long-term observation helps evaluate real-world treatment outcomes and patient health over time.

Age: 18Years +All Genders
27 locations
P

Actively Recruiting

Researchers are evaluating the use of oral ivosidenib in adults with locally advanced or metastatic conventional chondrosarcoma that has an IDH1 gene mutation. This Phase 3, international, multicenter, double-blind study compares ivosidenib to a placebo in participants who have measurable disease that has progressed or recurred and who have received up to two prior systemic treatments. The trial focuses on progression-free survival as the primary outcome, especially in Grades 1 and 2 chondrosarcoma participants. Participants will be randomly assigned to receive either ivosidenib 500 mg tablets or matching placebo tablets taken orally once daily. Treatment continues until disease progression confirmed by a blinded independent central review, unacceptable side effects, pregnancy, death, withdrawal, loss to follow-up, or study end. Those on placebo who experience disease progression and meet criteria may cross over to receive ivosidenib. The estimated average treatment duration is about two years. During the study, participants will undergo regular imaging scans to assess tumor response and progression according to RECIST criteria. Researchers will monitor survival outcomes up to five years and evaluate safety through adverse event reporting. Quality of life questionnaires and blood tests to measure drug and biomarker levels will be collected. The total participation duration may extend up to five years, including treatment and follow-up assessments.

Age: 18Years +All GendersPhase 3
115 locations
E

Actively Recruiting

Researchers are investigating the use of mocravimod as an additional and maintenance treatment for adults with acute myeloid leukemia AML who are undergoing allogeneic hematopoietic cell transplantation HCT. This phase III, multi-center, randomized, double-blind, placebo-controlled trial aims to assess the drugs safety and effectiveness in this patient population, focusing on improving relapse-free survival. Participants will be randomly assigned to one of three groups receiving 3 mg of mocravimod daily, 1 mg of mocravimod daily, or a placebo daily, all administered orally for 12 months. The study involves parallel groups and maintains quadruple masking to ensure unbiased results. During the trial, participants will be closely monitored with regular assessments to evaluate relapse-free survival over 12 months and overall survival over 24 months. Safety and efficacy will be observed throughout, with participants undergoing standard care alongside study treatments. The total participation duration aligns with the treatment and follow-up periods extending up to two years.

Age: 18Years - 75YearsAll GendersPhase 3
111 locations
M

Actively Recruiting

Researchers are evaluating the long-term safety of the drug ONO-4538 in participants with various types of tumors. This phase II study includes individuals who have previously been treated with ONO-4538 either alone or combined with other therapies in clinical trials. The goal is to monitor safety over an extended period to better understand the effects of continuing ONO-4538 treatment. Participants receive ONO-4538 either as monotherapy or in combination with other treatments such as S-1 plus oxaliplatin, capecitabine plus oxaliplatin, bevacizumab, temozolomide, ipilimumab plus combination therapies, or ONO-7703. ONO-4538 is given by intravenous infusion every 2 to 4 weeks depending on the investigators choice, while combination therapies include various oral and intravenous drugs administered according to specific schedules. The study continues the treatment regimens from prior clinical trials. During the study, participants are monitored for adverse events from the start of treatment until 28 days after the treatment phase ends. Researchers assess safety through regular evaluations and record any side effects experienced. Participation continues as long as treatment is ongoing, helping to provide detailed long-term safety data for ONO-4538 in this patient population.

Age: 16Years +All GendersPhase 2
44 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the Enzeavour Pancreatic Cancer assay as a screening tool for pancreatic cancer in asymptomatic adults in Japan. This nationwide, multicenter, prospective, single-arm feasibility study aims to assess the detection rate and positive predictive value of this blood-based test in routine health checkups and cancer screening programs. Pancreatic cancer is often diagnosed late, and this study seeks to develop an effective population-based screening strategy. Participants will have blood samples collected during routine health checkups or organized cancer screenings. The Enzeavour assay measures the activity of three specific enzymes at a single-molecule level and combines four biomarkers into a composite score. Those with an Enzeavour Score above 0.369 will be referred for further diagnostic imaging such as MRCP, EUS, or contrast-enhanced CT as needed. This diagnostic work-up follows the initial screening result. Throughout the study, which follows participants for 12 months after the blood draw, researchers will monitor pancreatic cancer detection rates and the assays positive predictive value. Participants will be evaluated through blood tests and any indicated diagnostic imaging. The study will include approximately 10,000 adults and aims to provide real-world data for planning future trials. The total duration of participation varies based on follow-up needs.

Age: 20Years +All GendersPhase Not Applicable
69 locations

1-10 of 17

1